Leerink raises target for McKesson stock from USD 1,030 to USD 1,070

Published on 10/20/2026 at 11:26 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

McKesson stock costs EUR 904.50 on October 20, 2026 ahead of results. Second-quarter fiscal 2027 results are due after market close on November 4, 2026.

McKesson events and valuation

McKesson extended its CVS distribution agreement through June 2032 on October 1, 2026.
Fiscal first-quarter revenue reached USD 105.38 billion, up 7.70 percent year over year.
McKesson stock trades at EUR 904.50 at 11:14 a.m. CEST at Lang & Schwarz on October 20, 2026.
Leerink Partners raised its target from USD 1,030.00 to USD 1,070.00 on October 7, 2026.
Second-quarter fiscal 2027 results are scheduled for November 4, 2026.

Comic-Illustration im Pop-Art-Stil zeigt Apotheker der Kundin eine Tüte überreicht — Pop-Art-Comic-Szene einer Apothekenübergabe visualisiert farbenfroh das Kerngeschäft von McKesson Corporation ISIN US58155Q1031 heiter und freundlich, Illustration mit AI erstellt.

McKesson Corporation (US58155Q1031) was the subject of a higher Leerink Partners target on October 7, 2026, when the firm raised its target from USD 1,030.00 to USD 1,070.00 while maintaining an Outperform rating, according to GuruFocus. The move gives investors a concrete valuation marker as McKesson prepares to report its next quarter.

CVS agreement extends through 2032

On October 1, 2026, McKesson announced an agreement in principle to extend its pharmaceutical distribution partnership with CVS Health through June 2032. The arrangement covers mail-order and specialty pharmacies, retail pharmacies, and distribution centers, while McKesson reaffirmed fiscal 2027 adjusted earnings-per-share guidance of USD 44.20 to USD 45.00, according to McKesson. The company also set its long-term adjusted earnings-per-share growth rate at 13.00 percent to 16.00 percent.

What does the target mean for earnings?

The valuation discussion follows fiscal first-quarter results for the period ended June 30, 2026. Revenue rose 7.70 percent year over year to USD 105.38 billion, while adjusted earnings per share increased 20.20 percent to USD 9.93, according to Financial Report Insights. GAAP diluted earnings per share fell 17.60 percent to USD 5.15 because of a USD 293.00 million non-cash charge connected with the Medical-Surgical business stake.

Three dated McKesson developments

On August 5, 2026, McKesson reported fiscal first-quarter revenue of USD 105.38 billion and adjusted earnings per share of USD 9.93. On October 1, 2026, it extended the CVS agreement through June 2032 and reaffirmed adjusted earnings-per-share guidance of USD 44.20 to USD 45.00. On October 7, 2026, Leerink Partners raised its target from USD 1,030.00 to USD 1,070.00.

Next reporting dates

McKesson will release second-quarter fiscal 2027 results after market close on November 4, 2026. The company will host its earnings webcast at 4:30 p.m. ET on November 4, 2026, according to McKesson.

Stock valuation remains measurable

McKesson's primary listing is on the NYSE, where the stock was last at USD 1,010.43 on October 19, 2026 at 4:00 p.m. ET. Its market capitalization was USD 117.8 billion, and its 52-week range was USD 723.68 to USD 1,014.99 as of that date. The range leaves the shares near the upper end of their recent trading band, while the Leerink target offers a separate analyst benchmark.

McKesson was trading at EUR 904.50 at Lang & Schwarz on October 20, 2026 at 11:14 a.m. CEST.

The further course of trading is shown by the continuously updated real-time quote of McKesson stock.